UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000052907
Receipt number R000060368
Scientific Title Establishment of ketogenic diet therapy guidance in Japanese patients with ADPKD
Date of disclosure of the study information 2023/11/27
Last modified on 2023/11/26 21:26:32

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Establishment of ketogenic diet therapy guidance in Japanese patients with ADPKD

Acronym

Ketogenic diet therapy in Japanese ADPKD

Scientific Title

Establishment of ketogenic diet therapy guidance in Japanese patients with ADPKD

Scientific Title:Acronym

Ketogenic diet therapy in Japanese ADPKD

Region

Japan


Condition

Condition

Autosomal dominant polycystic kidney

Classification by specialty

Nephrology Urology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

This study will examine the usefulness and tolerability of web-based tools for dietary guidance and nutritional management for patients with autosomal manifest polycystic kidney disease (ADPKD).

Basic objectives2

Safety

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Health status assessment (baseline and 3, 6, 9, and 12 months)
Height, weight, BMI, abdominal circumference, blood pressure
Blood samples (blood count, biochemistry; BUN, Cre, AST, ALT, LDH, ALP, T-Bil, D-Bil, fasting blood sugar, total-LDL-HDL-cholesterol, TG, HbA1c, CRP, adiponectin, leptin, ghrelin)
Urine (specific gravity, PH, protein, ketone bodies, white blood cells, red blood cells, glucose, creatinine, Na, Pi)
Height-adjusted total kidney volume (hTKV) from MRI or other imaging studies (at baseline and 12 months only, not exceeding the range of actual clinical kidney volume measurements)
(Not to exceed the range of actual clinical renal volume measurements at baseline and 12 months only)
Home measurements of blood ketone levels, blood glucose levels, and urinary Ph: daily for 1-12 weeks, weekly thereafter.
Only these three items will be collected at home. Only these three items will be collected at home, and the others at the hospital.

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Self control

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Food Behavior,custom

Interventions/Control_1

Change diet to a plant-based ketogenic diet

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit

85 years-old >=

Gender

Male and Female

Key inclusion criteria

(1) Male or female, 18 years of age or older
(2) Have a confirmed diagnosis of ADPKD based on ADPKD guidelines
(3) Estimated glomerular filtration rate (eGFR) >30 mL/min/1.73 m2 at screening (according to [CKD-EPI] formula)
(4) Female participants are not pregnant or lactating or planning to become pregnant or lactating during the study period
(5) Able to read, understand, and respond to the survey form
(6) Have no problems with the web environment and are able to take online classes. Also, able to complete the form online
(7) Have voluntary written consent to participate in the study

Key exclusion criteria

(1) poorly controlled diabetes mellitus with HbA1C > 8.0
(2) Uncontrolled dyslipidemia with LDL cholesterol > 4 mmol/L or triglycerides > 3 mmol/L
(3) Uncontrolled hypertension (SBP > 160 and/or BP > 100 mm Hg on 3 occasions)
(5) Hyperkalemia (>5.5 mmol/l).
(6) Significant disease such as malignancy within the past 5 years, autoimmune disease under immunosuppressive treatment
(8) On any medication (SGLT2 inhibitor) or investigational drug that may affect the safety of the ketogenic diet (since bardoxolone methyl for ADPKD is under investigation in Japan).
(12) Food sensitivities or allergies incompatible with the nutritional program
(13) Subject is already compliant with a ketogenic diet or fasting
(14) Current or past history of eating disorders or eating behaviors
(16) Ulcerative colitis, irritable bowel syndrome, Crohn's disease, or gallbladder disease
(17) BMI less than 18

Target sample size

100


Research contact person

Name of lead principal investigator

1st name Shigeo
Middle name
Last name Horie

Organization

Juntendo University Graduate School of Medicine

Division name

Department of Urology

Zip code

113-8421

Address

2-1-1, Hongo, Bunkyo-ku, Tokyo, Japan

TEL

0338133111

Email

harunase@juntendo.ac.jp


Public contact

Name of contact person

1st name Haruna
Middle name
Last name Kawano

Organization

Juntendo University Graduate School of Medicine

Division name

Department of Urology

Zip code

113-8421

Address

2-1-1, Hongo, Bunkyo-ku, Tokyo, Japan

TEL

0338133111

Homepage URL


Email

harunase@juntendo.ac.jp


Sponsor or person

Institute

Department of Urology, Juntendo University Graduate School of Medicine

Institute

Department

Personal name



Funding Source

Organization

Department of Urology, Juntendo University Graduate School of Medicine

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Juntendo University Graduate School of Medicine

Address

2-1-1, Hongo, Bunkyo-ku, Tokyo, Japan

Tel

0338133111

Email

hongo-rinri@juntendo.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2023 Year 11 Month 27 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2023 Year 09 Month 19 Day

Date of IRB

2023 Year 09 Month 19 Day

Anticipated trial start date

2023 Year 12 Month 18 Day

Last follow-up date

2025 Year 10 Month 18 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2023 Year 11 Month 26 Day

Last modified on

2023 Year 11 Month 26 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000060368


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name